Key result
Edoxaban monotherapy resulted in a lower risk of major or clinically relevant nonmajor bleeding and a similar risk of major ischemic events compared to dual antithrombotic therapy at 12 months.
Why the study?
Does edoxaban monotherapy reduce bleeding compared to dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease?
Does edoxaban monotherapy reduce bleeding compared to dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease?
In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy reduces bleeding risk without increasing ischemic events compared to dual antithrombotic therapy.
To the Editor: In the EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial, Cho et al. (Dec. 5 issue) 1 found that edoxaban monotherapy resulted in a lower risk of major or clinically relevant nonmajor bleeding than dual antithrombotic therapy, as well as in a similar risk of major ischemic events, at 12 months among patients with atrial fibrillation and stable coronary artery disease. The results of the EPIC-CAD trial differ from those of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) . . .
No takes yet. Share an insight, caveat, or question.
Nam et al. (2025) conducted a letter in Atrial fibrillation and stable coronary artery disease. Edoxaban monotherapy vs. Dual antithrombotic therapy (Edoxaban with Antiplatelet Agent) was evaluated on Major or clinically relevant nonmajor bleeding and major ischemic events. Edoxaban monotherapy resulted in a lower risk of major or clinically relevant nonmajor bleeding and a similar risk of major ischemic events compared to dual antithrombotic therapy at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: